What is the current price of PRFN.SW stock and recent price action?

PRFN.SW stock traded at **CHF 0.0362** pre-market on 17 Feb 2026, down **8.12%** for the session. Volume was **2,937,350**, about **3.42x** the average, indicating heavy trading interest.

What grade does Meyka AI give PRFN.SW stock and what does it mean?

Meyka AI rates PRFN.SW **59.53/100 (C+, HOLD)**. The grade combines benchmark and sector comparison, financial metrics, growth and analyst signals. It is informational, not investment advice.

What are realistic price targets for PRFN.SW stock?

Meyka AI's model gives a base-case target **CHF 0.06**, conservative **CHF 0.03**, and bullish **CHF 0.12**. These are model projections and not guarantees; liquidity and clinical risk remain key.

Where can I find official company information for PRFN.SW stock?

Official details and company updates are on the Kinarus site: [Kinarus Therapeutics](https://www.kinarus.com). Financial profile data is also available at [FinancialModelingPrep](https://financialmodelingprep.com).

CH Stocks

PRFN.SW stock down 8.12% pre-market at CHF 0.0362: heavy volume and model outlook

ByHuzaifa Zahoor February 17, 2026February 17, 2026

PRFN.SW stock is trading as one of Switzerland’s most active pre-market names after an 8.12% decline to CHF 0.0362 on 17 Feb 2026 on unusually high volume of 2,937,350 shares. The move follows thin market depth and a wide gap from the 50-day average price of CHF 0.07. Traders on the SIX are pricing in higher short-term volatility while investors weigh clinical progress for Kinarus Therapeutics Holding AG and limited cash reserves.